AHASTAT blog: Reducing 340B is not the answer to curbing skyrocketing drug prices

Mar 08, 2016 - 04:28 PM

A recent proposal that calls for reducing the benefits of the 340B Drug Pricing Program to curb rapidly rising prescription drug costs is “misguided,” writes AHA Executive Vice President Tom Nickels in an AHASTAT blog post today. Responding to a recent opinion piece in the New England Journal of Medicine, Nickels said, “The 340B program is more important now than ever before as the prices of prescription drugs continue to skyrocket. Instead of trying to make changes to a program with a strong track record of increasing access to care for patients in vulnerable communities, policymakers should consider other solutions, such as requiring greater transparency on drug pricing and charity policies by drug companies, increased competition in the generic industry or other reasonable proposals.” For more on the 340B program, visit www.aha.org/protect340B.

Related News Articles

Headline
CMS, FDA announce pathway to expedite access to certain medical devices for Medicare beneficiaries
The Centers for Medicare & Medicaid Services and the Food and Drug Administration April 23 announced a new pathway to expedite access to certain FDA-…
Blog
Why Paragon Gets Hospitals Wrong: Report Ignores Reality of Care Delivery
Public
In think‑tank reports, like the one released this week by Paragon Health Institute, hospitals are often reduced to abstractions — payment rates, charts,…
Headline
CMS delays Part D portion of BALANCE Model on expansion of GLP-1 access
The Centers for Medicare & Medicaid Services announced in a memo April 21that it is delaying implementation of the Medicare Part D portion of the Better…
Headline
DOJ updates Title II web, app nondiscrimination rule timelines for state and local governments; HHS Section 504 rules remain unchanged
As published April 20, the Department of Justice released an interim final rule in the Federal Register to delay compliance dates for states and local…
Headline
Washington Post publishes AHA letter in response to anti-340B editorial
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
AHA releases Q1 2026 Health Care Plan Accountability Update
The AHA today released its Health Care Plan Accountability Update, covering the latest developments in Medicare Advantage, legislation and…